Vertex Pharmaceuticals (VRTX) Notes Payables (2010 - 2017)
Vertex Pharmaceuticals' (VRTX) quarterly Notes Payables came in at $232.4 million in Q4 2017, up 216.55% year-on-year from $73.4 million in Q4 2016, and up 22.14% quarter-over-quarter from $190.3 million in Q3 2017.
Vertex Pharmaceuticals (VRTX) Notes Payables (2010 - 2017) Analysis & Trends
Vertex Pharmaceuticals' Notes Payables history runs 4 years deep, the most recent figure standing at $232.4 million for Q4 2017.
- On a quarterly basis, Notes Payables rose 216.55% year-over-year to $232.4 million in Q4 2017; TTM through Dec 2017 was $232.4 million, a 216.55% increase from a year earlier, with the FY2017 full-year figure at $232.4 million, up 216.55% from the prior year.
- Notes Payables climbed to $232.4 million in Q4 2017 per VRTX's latest filing, from $190.3 million in the prior quarter.
- Across five years, Notes Payables topped out at $232.4 million in Q4 2017 and bottomed at $73.4 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 232.40 Mn |
| Sep 30, 2017 | 190.27 Mn |
| Jun 30, 2017 | 147.69 Mn |
| Mar 31, 2017 | 104.77 Mn |
| Dec 31, 2016 | 73.42 Mn |
| Sep 30, 2011 | 94.16 Mn |
| Mar 31, 2011 | 84.89 Mn |
| Dec 31, 2010 | 77.80 Mn |